EyeGene Inc. (185490.KQ)
- Previous Close
2,900.00 - Open
2,880.00 - Bid 2,865.00 x --
- Ask 2,890.00 x --
- Day's Range
2,845.00 - 2,920.00 - 52 Week Range
2,800.00 - 4,895.00 - Volume
53,116 - Avg. Volume
71,030 - Market Cap (intraday)
31.55B - Beta (5Y Monthly) 1.73
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculosis vaccine; and EG-HPV that has completed Phase I clinical trial for the treatment of cervical cancer. It also offers EG-Vac for the treatment of immune adjuvant; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-HZ, which has completes phase I trials for the treatment of herpes zoster. In addition, the company provides vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
www.eyegene.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 185490.KQ
Performance Overview: 185490.KQ
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 185490.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 185490.KQ
Valuation Measures
Market Cap
78.39B
Enterprise Value
34.77B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.31
Price/Book (mrq)
1.34
Enterprise Value/Revenue
12.11
Enterprise Value/EBITDA
-1.92
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.30%
Return on Equity (ttm)
-29.61%
Revenue (ttm)
2.87B
Net Income Avi to Common (ttm)
-16.61B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
45.72B
Total Debt/Equity (mrq)
5.41%
Levered Free Cash Flow (ttm)
-13.3B